HOME > COMMENTARY
COMMENTARY
-
<New Series> Pursuing the Value of the Japanese Pharm Industry (1)
January 19, 2004
-
<Special Contribution> Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
-
<Special Contribution> Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets
January 12, 2004
-
November 10, 2003
-
<Special Contribution>
November 3, 2003
-
<Special Contribution>
September 1, 2003
-
Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko President, Pharma Marketing Survey Research Laboratory
August 11, 2003
-
June 9, 2003
-
May 12, 2003
-
March 24, 2003
-
January 20, 2003
-
< Special Contribution >
January 13, 2003
-
BARKER ON DRUGS
December 23, 2002
-
BARKER ON DRUGS (10)
November 18, 2002
-
BARKER ON DRUGS (9)
October 14, 2002
-
Commentary 2 articles
October 7, 2002
-
Barker on Drugs (8)
September 9, 2002
-
Barkers on Drugs (7)
July 29, 2002
-
BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
-
BARKER ON DRUGS(5)
June 3, 2002
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
